Articles

Poll

Podcasts

Slideshows

Videos

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

At Week 52, icotrokinra achieved clear/almost clear skin in 72% of patients with scalp psoriasis and 85% with genital psoriasis, with consistent safety and durable responses.

Oral IL-23 Blocker Icotrokinra Sustains High Clearance in Scalp and Genital Psoriasis

Panelists discuss how the head-to-head ICONIC-ADVANCE studies demonstrated icotrokinra’s superior efficacy vs deucravacitinib, with approximately double the complete clearance rates and a safety profile similar to placebo.

Expert Perspectives on Key Results From ICONIC-ADVANCE 1 and 2 Trials

Panelists discuss how icotrokinra represents a novel oral peptide that selectively blocks the IL-23 receptor, offering the trusted safety profile of IL-23 inhibition in an oral formulation with high selectivity and no off-target effects.

Discussing New Data on Novel Oral Peptide for Psoriasis

This systematic review and meta-analysis highlights tildrakizumab’s efficacy in Asian patients versus the efficacy of other biologic options.

Tildrakizumab Efficacy Similar to Other Psoriasis Biologics Among Patients in Asia

This conference preview for the 2025 Fall Clinical Dermatology meeting highlights upcoming sessions and interviews.

Conference Preview: Fall Clinical Dermatology Conference 2025

A study found no major differences in overall cancer risk among adalimumab, secukinumab, and ustekinumab for psoriasis.


Ustekinumab Linked to Lower 5-Year Cancer Risk vs Adalimumab in Psoriasis

SelectION, Inc. has announced positive topline findings from its phase 1b proof-of-concept study assessing si-544 in those with psoriasis vulgaris.

Investigational Drug si-544 Improves PASI Scores in Patients with Psoriasis

JAK inhibitors have transformed the world of treatment for inflammatory disease, and views on their safety and efficacy have also transformed over the years.

Rethinking the Black Box: JAK Inhibitors Find Their Place in Dermatology

Acitretin, Methotrexate Show Greater Maintenance Versus Cyclosporine in Pediatric Psoriasis

This systematic review and meta-analysis of available randomized controlled trials compared biologics for psoriasis, such as ixekizumab, secukinumab, and ustekinumab.

Biologics Compared in Systematic Review for Moderate-to-Severe Pediatric Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Plaque Psoriasis